PT-141vsRetatrutide
PT-141 vs Retatrutide — independent comparison of uses, administration, pricing across providers, and key differences. Last reviewed April 21, 2026.
Quick Verdict
Based on clinical evidence and real patient data
A melanocortin receptor agonist that works through the central nervous system to improve sexual arousal. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Best choice depends on your insurance, budget, and treatment history.Take the quiz to get a personalized recommendation.
PT-141 vs Retatrutide: At a Glance
Full comparison across all key factors.
| Factor | PT-141ALLY PICK | Retatrutide |
|---|---|---|
| Category | sexual-health | weight-loss |
| Also Known As | Bremelanotide, Vyleesi | LY3437943 |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Prescription | Required | Required |
| Providers | 5 providers✓ Better | 3 providers |
| Common Uses |
|
|
Data sourced from FDA prescribing information and peer-reviewed clinical trials. Prices reflect telehealth platform costs as of April 21, 2026. See our methodology.
Pricing by Provider
3 providers offer both PT-141 and Retatrutide.
| Provider | PT-141 | Retatrutide | Consultation | Lab Testing |
|---|---|---|---|---|
 | $150/per-vial | $450/monthly | Video Telehealth | Yes |
 | $160/monthly | $480/monthly | Video Telehealth | Yes |
 | $200/monthly | $550/monthly | Video Telehealth | Yes |
 | $30/one-time | Not offered | Async Telehealth | No |
 | $140/monthly | Not offered | Video Telehealth | No |
Key Differences
PT-141
More ProvidersA melanocortin receptor agonist that works through the central nervous system to improve sexual arousal. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Which Is Right for You?
Choose PT-141if…
- You want a sexual-health medication
- You prefer subcutaneous injection administration
- You want more provider options (5 available)
- Your primary goal is sexual dysfunction
- Your primary goal is low libido
Choose Retatrutideif…
- You want a weight-loss medication
- You prefer subcutaneous injection (weekly) administration
- 3 providers available on our platform
- Your primary goal is weight loss
- Your primary goal is metabolic health
Frequently Asked Questions
What is the difference between PT-141 and Retatrutide?
Which is cheaper, PT-141 or Retatrutide?
Can I switch from PT-141 to Retatrutide?
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary. The information presented reflects publicly available data and may not account for your specific health situation.
Related Guides
PT-141 for Sexual Health: Complete Provider Options & Cost Guide 2026
Read guide →Read guide →Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything
Complete guide to retatrutide — Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) with 28.7% weight loss in trials. Clinical data, how it compares, and when it might be available.
Read guide →Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?
No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.
Read guide →